Regulatory News:
Medivir (STO:MVIRB)
Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data
for simeprevir, an NS3 / 4A protease inhibitor for the treatment of
hepatitis C virus infection, will be presented by our partner Janssen
Sciences Ireland UC (Janssen) in conjunction with The International
Liver Congress ™ 2016 of the European Association for the Study of the
Liver (EASL) in Barcelona, on 13-17 April. A total of nine presentations
will be made, including one "late breaker" presentation. The
presentations will cover the efficacy, safety and tolerability of
simeprevir used as a component of various combination therapies in a
number of different adult patient populations, and will be based on data
from phase II and phase III studies and from on-going clinical use
(so-called "real-world data").
Data presented at the International Liver Congress 2015 include:
Late-Breaking Poster Presentation
Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: a
phase 3, open-label study.
· Abstract LBP516
· Lead Author: M. Buti; Hospital Vall d’Hebron and Centro Investigación
Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd),
Barcelona, Spain
Poster Presentations
Pharmacokinetic interactions between simeprevir and ledipasvir in
treatment-naïve hepatitis C virus genotype 1-infected patients without
cirrhosis treated with a simeprevir/sofosbuvir/ledipasvir regimen
· Abstract SAT-264
· Lead Author: S. Bourgeois, Department of Internal Medicine, ZNA
Ster, Antwerp
Deep sequencing results from the Phase 2 IMPACT study of simeprevir in
combination with daclatasvir and sofosbuvir in treatment-naïve
and -experienced patients with chronic hepatitis C virus genotype 1 or 4
infection and decompensated liver disease
· Abstract THU-215
· Lead Author: C. Sarrazin, Johann Wolfgang Goethe University Medical
Center, Frankfurt am Main, Germany
Consistent simeprevir resistance profile in hepatitis C virus genotype
1-infected patients failing simeprevir interferon-free compared with
interferon-containing regimens
· Abstract THU-214
· Lead Author: B. Fevery, Janssen Infectious Diseases BVBA,
Beerse, Belgium
Effectiveness of simeprevir-containing regimens among patients with
chronic hepatitis C virus in various US practice settings: The SONET
study
· Abstract SAT-167
· Lead Author: I. Alam, Austin Hepatitis Center, Austin, TX, USA
Efficacy and safety of simeprevir and sofosbuvir with and without
ribavirin for 12 weeks in subjects with recurrent genotype 1 hepatitis C
post-orthotopic liver transplant: The GALAXY study
· Abstract FRI-457
· Lead Author: J.G. O'Leary, Baylor University Medical Center, Dallas,
TX, USA
Efficacy and tolerability of simeprevir and daclatasvir for 12 or 24
weeks in HCV genotype 1b-infected treatment-naïve patients with advanced
fibrosis or compensated cirrhosis
· Abstract SAT-130
· Lead Author: C. Hézode, Department of Hepatology and Gastroenterology,
Hôpital Henri Mondor, Université Paris-Est, France
Effectiveness of simeprevir treatment for hepatitis C in real practice:
preliminary results from the STIly Italian observational study
· Abstract SAT-162
· Lead Author: G.B. Gaeta, Seconda Universita di Napoli, Napoli, Italy
Safety of simeprevir-based treatment for hepatitis C in real practice:
preliminary results from the STIly observational study
· Abstract SAT-212
· Lead Author: M. Colombo, Ospedale Maggiore Policlinico, Milano, Italy
Details of all presentations for The International Liver Congress ™ 2016
are available at the conference website: http://www.ilc-congress.eu
Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was submitted
for publication at 15.30 CET on 11 April 2016.
About Medivir
Medivir is a research based pharmaceutical company with a research focus
on oncology and infectious diseases. We have a leading competence within
protease inhibitor design and nucleotide/nucleoside science and we are
dedicated to develop innovative pharmaceuticals that meet great unmet
medical need. Our commercial organization provides a portfolio of
specialty care pharmaceuticals on the Nordic market. Medivir is listed
on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160411005813/en/
Copyright Business Wire 2016